🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

US STOCKS-Futures tumble as stimulus doubts resurface

Published 12/11/2020, 08:04 PM
Updated 12/11/2020, 08:10 PM
© Reuters.
US500
-
DJI
-
VIX
-

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window.)
* Futures down: Dow 0.9%, S&P 1%, Nasdaq 1%

By Shriya Ramakrishnan
Dec 11 (Reuters) - U.S. stock index futures fell 1% on
Friday as delays over a new fiscal stimulus package and surging
coronavirus infections dented sentiment even as regulators moved
toward emergency use authorization of a COVID-19 vaccine.
With fresh business restrictions in many states and a jump
in weekly jobless claims, investors are counting on more fiscal
relief to sustain a nascent economic recovery.
But an agreement remains elusive and House Speaker Nancy
Pelosi on Thursday raised the possibility of negotiations
dragging on through Christmas.
Cyclical stocks, which stand to benefit from an economic
recovery, led declines in premarket trading on Friday, with
energy, industrial and financial sectors all lower.
Major banks Wells Fargo & Co WFC.N and JPMorgan Chase & Co
JPM.N slid more than 1%, while industrial bellwethers Boeing
Co BA.N and 3M Co MMM.N fell 1.6% and 0.9%, respectively.
The benchmark S&P 500 .SPX and the blue-chip Dow .DJI
were set to snap a two-week winning streak as volatility .VIX
jumped to its highest in almost a month.
At 06:29 a.m. ET, Dow E-minis 1YMcv1 were down 270 points,
or 0.89%, S&P 500 E-minis EScv1 were down 37.5 points, or
1.02%, and Nasdaq 100 E-minis NQcv1 were down 125.75 points,
or 0.98%.
Global stock markets were also subdued after scaling record
highs earlier this week as the UK became the first country in
the world to begin a mass COVID-19 vaccination program.
MKTS/GLOB
A panel of outside advisers to the U.S. Food and Drug
Administration on Thursday voted overwhelmingly to endorse
emergency use of Pfizer's PFE.N COVID-19 vaccine, sending
shares of the drugmaker up 1.9% in premarket trading.
Mastercard MA.N dropped 1.4% after the UK Supreme Court
gave the green light for a $18.5 billion class action against
the company for allegedly overcharging more than 46 million
people in Britain over a 15-year period.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.